OncoLens

What OncoLens does

OncoLens is an Atlanta-based digital health company that provides an AI-enabled platform for multidisciplinary oncology care coordination, serving U.S. cancer centers, integrated delivery networks, academic medical centers, and life sciences companies. Founded in 2016/2017 by Anju Mathew and Dr. Lijo Simpson, the company originated from tumor board management workflows and has expanded into a multi-module SaaS platform spanning tumor board automation (OncoLens Conference), AI-driven patient identification for clinical trials and biomarker testing (OncoLens Patient ID), biomarker-based treatment planning with lab partner integrations (OncoLens Molecular), cross-organization case collaboration (OncoLens Collaborate), and analytics with automated registry and accreditation reporting (OncoLens Analytics). The platform integrates with major ONC-certified EMRs (Epic, Cerner, OncoEMR, athenahealth, Mosaiq, ARIA) and leverages proprietary oncology-focused large language models and NLP to extract insights from unstructured clinical and lab data.

The underlying technology combines LLMs fine-tuned on oncology-specific keywords with proprietary knowledge models, processing structured and unstructured EMR data including clinical notes, pathology, radiology imaging, and genomic results. OncoLens claims 85-90% accuracy in AI-driven patient identification from unstructured data, 80% cancer staging extraction from clinical notes, and trial matching against up to 90% of clinical trial inclusion/exclusion criteria. The platform is SOC 2 Type II certified and HIPAA compliant, and is built on cloud data infrastructure including Snowflake and dbt.

OncoLens operates a sales-led enterprise go-to-market targeting two primary verticals: provider organizations (cancer centers, hospitals, IDNs) and life sciences companies (pharma, biotech, CROs). Revenue is generated through subscription-based SaaS licensing with quote-based enterprise pricing for providers, and through the OncoLens Research Network (ORN), which connects 220+ cancer centers with life sciences partners for clinical trial matching, real-world data access, biomarker testing analysis, and market launch support. The company reports 5,000,000+ oncology patients under care within its network, 45,000+ multidisciplinary physicians, and partnerships with 50% of the top 20 pharma companies, and has raised approximately $27.85M in disclosed funding through Series B.

Name

OncoLens

Legal name

OncoLens

Website

https://oncolens.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

OncoLens is an AI-enabled oncology platform serving U.S. cancer centers, integrated delivery networks, and life sciences companies with tumor board management, clinical trial patient identification, biomarker treatment planning, and real-world data analytics.

Ownership category

akta.pro rank

Product category

Oncology Care Coordination Software

NAICS

Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (51821)

SIC

Services-Prepackaged Software (7372), Services-Health Services (8000), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD)

Keywords

• Oncology care software
• Tumor board platform
• Clinical trial matching
• Cancer analytics solutions
• Biomarker treatment planning

Headquarters

HQ city

Atlanta

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

1. SaaS Platform Subscription: Subscription-based SaaS platform for cancer centers providing multidisciplinary care coordination, tumor board management, analytics, and patient identification services. Delivered as cloud-based platform with enterprise licensing.
2. Life Sciences Research Network: Revenue from life science companies (pharma, CROs) accessing the OncoLens Research Network for clinical trial matching, site identification, feasibility analysis, real-world data, and quality improvement initiatives.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

OncoLens is an AI-enabled digital healthcare platform that delivers oncology workflow and analytics solutions grounded in information extracted from structured and unstructured clinical and lab data. The platform offers modules for tumor board management, real-time patient identification, molecular biomarker-based treatment planning, cross-organization case collaboration, and clinical trial matching, sold as enterprise SaaS subscriptions to cancer centers, health systems, and life sciences companies.

Product overview

OncoLens is an AI-enabled digital healthcare platform delivering a comprehensive suite of oncology workflow and analytics solutions. The platform consists of a core unified platform with integrated modules including: OncoLens Analytics (AI-powered dashboards and automated registry reporting), OncoLens Patient ID (real-time patient identification for trials and therapies), OncoLens Conference (tumor board management and workflow automation), OncoLens Collaborate (cross-organization case collaboration and referrals), OncoLens Molecular (biomarker-based treatment planning with lab partner integrations), and OncoLens Research Network (ORN, connecting cancer centers with life science companies). For life sciences partners, additional modules cover Clinical Trials, Precision Oncology, Real World Data and Insights, Market Launch Support, and Rare Disease patient identification. The platform processes both structured and unstructured clinical data to power clinical decision support, automate workflows, and improve patient outcomes across more than 220 cancer centers in the US network.

Differentiator

Problem solved

Functional benefit

Brands

• OncoLens Research Network (ORN): A research network connecting Life Science companies with community and academic cancer centers for clinical trials, quality improvement, and real-world data initiatives.

Products and services

• OncoLens Platform AI-enabled digital healthcare platform delivering workflow and analytics solutions grounded in information extracted from unstructured clinical and lab data for cancer care optimization, sold as a SaaS subscription to cancer centers, health systems, and life sciences companies.
• OncoLens Analytics AI-powered analytics module delivering real-time dashboards, automated registry reports, patient journey dashboards by cancer type, and cancer care operational insights. Supports accreditation reporting for CoC, NAPBC, NAPRC, and QOPI.
• OncoLens Patient ID Real-time patient identification and alerts module for clinical trials, biomarker testing, CAR-T, radioligand therapies, and targeted therapies. Uses AI/LLM with proprietary oncology knowledge models to match patients to trials and services with 85-90% accuracy on unstructured data.
• OncoLens Conference Intelligent workflow automation and real-time insights module for tumor board management. Integrates evidence-based protocols, automates pathology and radiology data collection, and streamlines accreditation tasks.
• OncoLens Collaborate Asynchronous case submission and review module with secure sharing of PACS studies, pathology images, and test results. Enables collaboration within oncology programs and with external institutions, supporting up to 50% increase in referrals.
• OncoLens Molecular Biomarker-based treatment planning and collaboration module with real-time insights from integrated lab partners (Caris, Guardant, Foundation Medicine, Tempus, Labcorp). Supports molecular tumor board discussions and targeted therapy recommendations.
• OncoLens Research Network (ORN) Research network connecting life science companies with 220+ community and academic cancer centers. Provides access to highly curated clinical trials, precision medicine initiatives, and real-world data, enabling revenue-driving opportunities for cancer centers.
• OncoLens Clinical Trials Clinical trial data, site identification, feasibility analysis, and AI-driven patient screening offered to life sciences companies via a diverse cancer center network. Supports clinical development, clinical operations, and CRO engagement.
• OncoLens Precision Oncology Solutions to close gaps in appropriate biomarker testing through patient alerts and quality improvement initiatives. Monitors testing completion rates and turnaround times for life science teams.
• OncoLens Real World Data and Insights Patient journey reports, biomarker testing analysis, competitive assessments, and community-based decision-making insights for life sciences. Delivers insight into oncology care through AI extraction from unstructured data.
• OncoLens Market Launch Support Digital engagement, educational campaigns, and quality improvement initiatives offered to life sciences teams to drive education on newly approved treatments or close gaps in existing practices.
• OncoLens Rare Disease AI-powered identification of patients with rare cancers or biomarker-defined subtypes for hyper-targeted therapies. Sends alerts to care teams for timely, potentially life-saving therapy intervention.

Quantifiable outcome

• Tumor board prep time reduced by up to 90%
• +8 more outcomes

Named customers9 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration14 records

AI capability8 records

Feature7 records

Partnerships

Five partnerships are on record, tiered major and minor.

• SARC (Sarcoma Alliance for Research Through Collaboration)majorStrategic or Co-development Partner · 2 June 2023Strategic partnership to launch nationwide virtual sarcoma tumor board program. OncoLens platform provides multidisciplinary tumor board capabilities for sarcoma care across the US.
• Association of Community Cancer Centers (ACCC)majorStrategic or Co-development Partner · 6 December 2022Partnership to power and disseminate Project ECHO eight-part webinar series on irAE monitoring and management. OncoLens network used to deliver education to cancer care providers.
• MIB AgentsmajorStrategic or Co-development Partner · 19 July 2022Partnership to support TURBO (Tumor Review Board for Osteosarcoma) program - virtual tumor board bringing together global osteosarcoma experts. OncoLens powers patient treatment discussions, care planning, and data collection for the program expanding globally.
• Desmoid Tumor Research FoundationmajorStrategic or Co-development Partner · 4 February 2022Virtualized tumor board program for desmoid tumors enabling international physician collaboration. OncoLens platform facilitates patient data sharing, treatment discussions, and documentation for rare tumor cases.
• Boston University Chobanian & Avedisian School of MedicineminorStrategic or Co-development PartnerCME accreditation partner for Project ECHO webinar series. BU CME designs and implements evidence-based education for the healthcare team.

Scale indicators15 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• LeanTaaS: Healthcare operations AI platform optimizing capacity, staffing, and patient flow across hospital systems. Broader than oncology but comparable in applying AI to provider workflow problems and selling enterprise SaaS to health systems.
• IQVIA: Global clinical research and life sciences services giant with extensive oncology trial matching, RWE, and healthcare data assets. Overlaps with OncoLens's Life Sciences offerings, particularly trial feasibility and real-world data.
• Merative (formerly IBM Watson Health): Healthcare data, analytics, and clinical decision support vendor with oncology offerings. Broader portfolio but overlaps with OncoLens's clinical decision support and analytics for providers.

Direct peers

• Flatiron Health: Roche-owned oncology-focused health technology company that aggregates real-world clinical and molecular data from cancer centers and serves both providers and life sciences. Highly comparable to OncoLens's dual provider/life-sciences model with deep oncology specialization.
• Syapse: Precision oncology real-world data platform partnering with community health systems and life sciences for oncology decision support. Comparable provider- and pharma-facing oncology data infrastructure.
• Tempus Labs: AI-enabled precision medicine company combining molecular profiling, real-world data, and AI tools for oncology providers and pharma. Competes directly with OncoLens in clinical trial matching, biomarker insights, and provider analytics.
• ConcertAI: Oncology-focused real-world evidence and AI company serving providers and life sciences with patient identification, trial matching, and outcomes analytics. Closest direct peer in the oncology RWE + trial enablement space.

Emerging players

• CancerIQ: Precision oncology platform focused on genetic risk assessment and hereditary cancer programs within health systems. Overlaps with OncoLens's biomarker testing and molecular workflow use cases but with a narrower hereditary focus.
• DeepHealth (DeepHealth Inc.): AI-driven medical imaging and health informatics company expanding into oncology diagnostics and population health. Adjacent technology overlap (AI on clinical imaging/data) for cancer centers.
• Inspirata (DynamiCare Health): Digital pathology and oncology workflow platform for tumor boards and cancer case review. Most direct functional overlap with OncoLens's tumor board and conference modules.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/oncolens
• Facebookfacebook.com/oncolens
• LinkedInlinkedin.com/company/lynkcare

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OncoLens